Lupus Nephritis
&nbsp;
Lupus nephritis (LN) is a common and potentially devastating manifestation of SLE. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli. Common signs of LN are hematuria, proteinuria, edema, and sudden weight gain.&nbsp;
&nbsp;
Lupus Nephritis Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Prevalent Population of Lupus Nephritis</li>
<li class="ql-align-justify">Total Diagnosed Population of Lupus Nephritis</li>
<li class="ql-align-justify">Gender-Specific Prevalent Population of Lupus Nephritis</li>
<li class="ql-align-justify">Class- Specific cases of Lupus Nephritis</li>
<li class="ql-align-justify">Clinical Manifestations of Lupus Nephritis</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/lupus-nephritis-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Lupus Nephritis Epidemiological Insights Observed in the 7MM (2021)</a>
&nbsp;
<ul>
<li class="ql-align-justify">The total incident cases of Lupus Nephritis observed in the 7MM were observed to be 209K cases in the year 2021</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/lupus-nephritis-market" target="_blank" rel="noopener noreferrer">Lupus Nephritis Market Insight</a>
&nbsp;
<ul>
<li class="ql-align-justify">The market size of Lupus Nephritis in the 7MM was found to be approximately USD 1,577 million in 2021. &nbsp;</li>
<li class="ql-align-justify">Amongst 7MM, the US accounted for the highest market size, which was approximately USD 975 million in the year 2021.&nbsp;</li>
<li class="ql-align-justify">In EU5, the market size was estimated to be approximately USD 392 million, whereas the market size of Japan was estimated to be USD 211.1 million in the year 2021.&nbsp;</li>
</ul>
&nbsp;
Market Drivers
&nbsp;
<ul>
<li class="ql-align-justify">Factors that hold the ability to drive the market include, Increase in research activities and an Increasing disease prevalence</li>
<li class="ql-align-justify">The &nbsp; Surge in the number of clinical studies can also be a driving factor&nbsp;</li>
</ul>
&nbsp;
<a style="background-color: transparent; color: #1155cc;" href="https://www.delveinsight.com/report-store/lupus-nephritis-pipeline-insight" target="_blank" rel="noopener noreferrer">Lupus Nephritis Emerging Drugs</a>
&nbsp;
The emerging drugs in the Lupus Nephritis market are
&nbsp;
<ul>
<li class="ql-align-justify">Obinutuzumab</li>
<li class="ql-align-justify">Anifrolumab, and others&nbsp;</li>
</ul>
&nbsp;
Lupus Nephritis Key Players&nbsp;
&nbsp;
The key players working in the Lupus Nephritis market are
&nbsp;
<ul>
<li class="ql-align-justify">AstraZeneca</li>
<li>Roche, and others</li>
</ul>

Lupus Nephritis Market

Lupus Nephritis Market Infographics

Lupus Nephritis Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape